Home > Archive>Volume 8, Issue 4, 2015 >653-658. DOI:10.3980/j.issn.2222-3959.2015.04.02
PDF HTML XML Export Cite reminder
Pharmacokinetics and distributions of bevacizumab by intravitreal injection of bevacizumab-PLGA microspheres in rabbits
Author:
Affiliation:

1Department of Ophthalmology, the First Affiliated Hospital of Dalian Medical University, Dalian 116011, Liaoning Province, China;
2The Institute of Clinical Medicine, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450003, Henan Province, China;
3Department of Ophthalmology, the Second People’s Hospital of Zhengzhou, Zhengzhou 450006, Henan Province, China

Fund Project:

Supported by National Natural Science Foundation of China (No.30973263, No.81370869)

  • Article
    • | |
  • Metrics
    • |
  • Reference [25]
    • |
  • Related [20]
    • | | |
  • Comments
    Abstract:

    AIM:To investigate the pharmacokinetics and distributions of bevacizumab by intravitreal injection of prepared bevacizumab-poly (L-lactic-co-glycolic acid) (PLGA) microspheres in rabbits, to provide evidence for clinical application of this kind of bevacizumab sustained release dosage form.METHODS:Bevacizumab was encapsulated into PLGA microsphere via the solid-in-oil-in-hydrophilic oil (S/O/hO) method. Fifteen healthy New Zealand albino-rabbits were used in experiments. The eyes of each rabbit received an intravitreal injection. The left eyes were injected with prepared bevacizumab-PLGA microspheres and the right eyes were injected with bevacizumab solution. After intravitreal injection, rabbits were randomly selected at days 3, 7, 14, 28 and 42 respectively, three animals each day. Then we used immunofluorescence staining to observe the distribution and duration of bevacizumab in rabbit eye tissues, and used the sandwich ELISA to quantify the concentration of free bevacizumab from the rabbit aqueous humor and vitreous after intravitreal injection.RESULTS:The results show that the concentration of bevacizumab in vitreous and aqueous humor after administration of PLGA formulation was higher than that of bevacizumab solution. The T1/2 of intravitreal injection of bevacizumab-PLGA microspheres is 9.6d in vitreous and 10.2d in aqueous humor, and the T1/2 of intravitreal injection of soluble bevacizumab is 3.91d in vitreous and 4.1d in aqueous humor. There were statistical significant difference for comparison the results of the bevacizumab in vitreous and aqueous humor between the left and right eyes (P<0.05). The AUC0-t of the sustained release dosage form was 1-fold higher than that of the soluble form. The relative bioavailability was raised significantly. The immunofluorescence staining of PLGA-encapsulated bevacizumab (b-PLGA) in rabbit eye tissues was still observed up to 42d. It was longer than that of the soluble form.CONCLUSION: The result of this study shows the beneficial effects of PLGA in prolonging the residency of bevacizumab in the vitreous. And the drug delivery system may have potential as a treatment modality for related disease.

    Reference
    1 Shahar J, Avery RL, Heilweil G, Barak A, Zemel E, Lewis GP, Johnson PT, Fisher SK, Perlman I, Loewenstein A. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006;26(3):262-269
    2 Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW Jr, Gonzalez S, Feuer WJ, Lin RC, Lalwani GA, Nguyen JK, Kumar G. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26(5):495-511
    3 Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration:a one-year prospective study. Am J Ophthalmol 2008;145(2):249-256
    4 Beer PM, Wong SJ, Hammad AM, Falk NS, O''Malley MR, Khan S. Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina 2006;26(8):871-876
    5 Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26(8):859-870
    6 Rosenfeld PJ，Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevaeizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36(4):331-335
    7 Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114(5):855-859
    8 Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ. Intravitreal bevacizumab treatment of choroidal neovasularization secondary to age-related macular degeneration. Retina 2006;26(4):383-390
    9 Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ, Wendel R, Patel A. Intravitreal bevacizumab(Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113(10):1695-1705
    10 Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS. Intravitreal bevaeizumab (Avastin) as treatment for subfoveal choroidal ncovaseularisation secondary to pathological myopia. Br J Ophthalmol 2007;91(2):157-160
    11 Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microsphere. Adv Drug Deliv Rev 1997;28(1):5-24
    12 Noriyuki Kuno, Hinobu Fujii. Recent advances in ocular drug delivery systems. Polymers 2011;3:193-221
    13 Vauthier C, Bouchemal K. Methods for the preparation and manufacture of polymeric nanoparticles. Pharm Res 2009;26(5):1025-1058
    14 Chen J, Jin T. Effect of formulation process of sustained-release PLGA microspheres on the protein activity and immunogenicity. Master Thsis, Shanghai Jiao Tong University 2008
    15 Spitzer MS, Wallenfels-Thilo B, Sierra A. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol 2006; 90(10):1316-1321
    16 Nomoto H, Shiraga F, Kuno N, Kimura E, Fujii S, Shinomiya K, Nugent AK, Hirooka K, Baba T. Pharmacokinetics of Bevacizumab after Topical, Subconjunctival, and Intravitreal Administration in Rabbits. Invest Ophthalmol Vis Sci 2009;50(10):4807-4813.
    17 Lee SS, Hughes P, Ross AD, Robinson MR. Biodegradable implants for sustained drug release in the eye. Pharm Res 2010;27(10):2043-2053
    18 Yang R, Chen TN, Chen HL, Wang WJ. Microfabrication of biodegradable (PLGA) honeycomb-structures and potential applications in implantable drug delivery. Sens Actuators B 2005; 106(2):506-551
    19 Abrishami M, Zarei-Ghanavati S, Soroush D, Rouhbakhsh M, Jaafari MR, Malaekeh-Nikouei B. Preparation, characterization, and in vivo evalution of nanoliposomes-encapsulated bevacizumab (Avastin) for intravitreal administration. Retina 2009;29(5):699-703
    20 Martinez-Sancho C, Herrero-Vanrell R, Negro S. Vitamin A palmitate and acyclovir biodegradable microspheres for intraocular sustained release.Int J Pharm 2006;326(1-2):100-106
    21 Moshfeghi AA, Peyman GA. Micro- and nanoparticulates. Adv. Drug Delivery Rev 2005;57(14):2047-2052
    22 Pan CK, Durairaj C, Kompella UB, Agwu O, Oliver SC, Quiroz-Mercado H, Mandava N, Olson JL. Comparison of Long-Acting Bevacizumab Formulations in the Treatment of Choroidal Neovascularization in a Rat Model. J Ocul Pharmacol Ther 2011;27(3):219-224
    23 Heiduschka P, Fietz H, Hofmeister S, Schultheiss S, Mack AF, Peters S, Ziemssen F, Niggemann B, Julien S, Bartz-Schmidt KU, Schraermeyer U; Tübingen Bevacizumab Study Group. Penetration of bevacizumab through the retinal after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007;48(6):2814-2823
    24 Peters S, Heiduschka P, Julien S, Bartz-Schmidt KU, Schraermeyer U. Immunohistochemical localization of intravitreally injected bevacizumab in the anterior chamber angle,iris and ciliary body of the primate eye. Br J Ophthalmol 2008;92(4):541-544
    25 Zhang L, Xu JS, Sanders VM, Letson AD, Roberts CJ, Xu RX. Multifunctional microbubbles for image-guided antivascular endothelial growth factor therapy. J Biomed Opt 2010;15(3):1-3
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

Zhuo Ye, Yan-Li Ji, Xiang Ma,/et al.Pharmacokinetics and distributions of bevacizumab by intravitreal injection of bevacizumab-PLGA microspheres in rabbits. Int J Ophthalmol, 2015,8(4):653-658

Copy
Share
Article Metrics
  • Abstract:2053
  • PDF: 784
  • HTML: 0
  • Cited by: 0
Publication History
  • Received:September 03,2014
  • Revised:January 19,2015
  • Adopted:January 19,2015
  • Online: July 27,2015
You are the 4403049 Visitors
Governing Body：Department of Health, Provincial Government of Shaanxi, China
Organizer：Xi'an Medical Association of China
Address：Room 11707-08, Building 2, Unit 1, Wanda Plaza, No.8 Yanta North Road, Xi'an 710054, Shaanxi Province, China
Fax：(8629)82245172 Phone：(+8629)82245172/82210956
Email：ijopress@163.com
International Journal of Ophthalmology ® 2025 All Rights Reserved   The terms of CC BY-NC-ND 4.0 are applicable to all open access content.